These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37985675)

  • 1. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
    Oriecuia C; Tomasoni D; Sala I; Bonfioli GB; Adamo M; Gussago C; Lombardi CM; Pagnesi M; Savarese G; Metra M; Specchia C
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):147-157. PubMed ID: 37985675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
    Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
    Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure: A Systematic Review and Meta-Analysis.
    Gao M; Bhatia K; Kapoor A; Badimon J; Pinney SP; Mancini DM; Santos-Gallego CG; Lala A
    JAMA Netw Open; 2024 Apr; 7(4):e245135. PubMed ID: 38573633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
    Gupta K; Spertus JA; Birmingham M; Gosch KL; Husain M; Kitzman DW; Pitt B; Shah SJ; Januzzi JL; Lingvay I; Butler J; Kosiborod M; Lanfear DE
    Circulation; 2023 Jul; 148(3):220-228. PubMed ID: 37191040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
    Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
    Tanashat M; Manasrah A; Abouzid M
    Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
    Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
    Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of SGLT2 Inhibitors on Quality of Life in Heart Failure Across the Ejection Fraction Spectrum: Systematic Review and Meta-analysis.
    Shah YR; Turgeon RD
    CJC Open; 2024 Apr; 6(4):639-648. PubMed ID: 38708049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
    Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
    Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
    Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials.
    Guo Z; Wang L; Yu J; Wang Y; Yang Z; Zhou C
    Int J Clin Pharm; 2023 Jun; 45(3):547-555. PubMed ID: 36800144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.